




PHARMACEUTICAL 2022

Verrica Pharmaceuticals Inc.
Rank 332 of 466





RealRate

PHARMACEUTICAL 2022

Verrica Pharmaceuticals Inc. Rank 332 of 466



The relative strengths and weaknesses of Verrica Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Verrica Pharmaceuticals Inc. compared to the market average is the variable Other Liabilities, increasing the Economic Capital Ratio by 19% points. The greatest weakness of Verrica Pharmaceuticals Inc. is the variable Liabilities, Current, reducing the Economic Capital Ratio by 108% points.

The company's Economic Capital Ratio, given in the ranking table, is 33%, being 45% points below the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	74,328
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	46,055
Liabilities, Non-Current	1,449
Other Assets	1,903
Other Compr. Net Income	-30
Other Expenses	0
Other Liabilities	16
Other Net Income	-4,172
Other Revenues	12,000
Property and Equipment	3,894
Research and Development	15,929
Selling, General and Administrative Expense	26,979

Output Variable	Value in 1000 USD
Assets	80,125
Liabilities	47,520
Expenses	42,908
Revenues	12,000
Stockholders Equity	32,605
Net Income	-35,080
Comprehensive Net Income	-35,095
Economic Capital Ratio	33%